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Abstract: Background: Shoulder pain is common in primary care. The management of subacromial
impingement (SAI) can include corticosteroid injections and physiotherapy. Physiotherapy can be
on an individual or group basis. Aim: To examine the clinical effectiveness and make an economic
analysis of individual versus group physiotherapy, following corticosteroid injection for SAI. Design
and Setting: A single-blind, open-label, randomised equivalence study comparing group and individual
physiotherapy. Patients referred by local general practitioners and physiotherapists were considered
for inclusion. Method: Patients were randomised to individual or group physiotherapy groups, and all
received corticosteroid injection before physiotherapy. The primary outcome measure was shoulder
pain and disability index (SPADI) at 26 weeks. An economic analysis was conducted. Results and
Conclusion: 136 patients were recruited, 68 randomised to each group. Recruitment was 68% of the
target 200 participants. SPADI (from baseline to 26 weeks) demonstrated a difference (SE) in mean
change between groups of −0.43 (5.7) (p-value = 0.050001), and the TOST (two-one-sided test for
equivalence) 90% CI for this difference was (−10.0 to 9.14). This was borderline. In a secondary analysis
using inputted data, patients without SPADI at week 26 were analysed by carrying forward scores at
week 12 (mean difference (95% CI) = −0.14 (−7.5 to 7.3), p-value = 0.014). There is little difference in
outcome at 26 weeks. Group physiotherapy was cheaper to deliver per patient (£252 versus £84). Group
physiotherapy for SAI produces similar clinical outcomes to individual physiotherapy with potential
cost savings. Due to low recruitment to our study, firm conclusions are difficult and further research is
required to give a definitive answer to this research question. (NCT Clinical Trial Registration Number
NCT04058522).
Keywords: shoulder; physiotherapy; group; subacromial impingement
1. Background
Shoulder pain is a common problem in the primary care population [1] causing significant
disability and morbidity [2–4]. There are numerous clinical diagnostic categories described for
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shoulder pain. However, subacromial impingement (SAI) is the most common category of shoulder
pain, encompassing several pathologies that reduce the subacromial space [5–7].
In primary care, SAI is commonly treated by corticosteroid injections and/or physiotherapy.
However, evidence for the effectiveness of these strategies is unclear [8–10]. Low quality evidence
suggests that subacromial corticosteroid injections have a small, positive short-term effect [9]. One review
suggests that exercises, as typically prescribed by physiotherapists [6], may be as effective as surgery.
Published guidelines state that exercises focused on the rotator cuff and scapular stabilizers are more
effective than general exercise; manual joint mobilisations bring no additional benefit when added to
an exercise regime, but soft tissue release/massage is more effective than placebo [11]. A study [12]
examining the cost-effectiveness of injection plus exercises compared to exercises alone for SAI reported
that, despite injection and exercises being more expensive, it may be a cost-effective strategy compared
with exercise alone. A review of the effectiveness of manual therapy and exercise suggested that
these may be similar in effectiveness to subacromial injection [10]. Further evidence is therefore
required to improve the management of SAI examining novel approaches or combinations of the above
treatments [10].
Physiotherapy is often given on a one-to-one basis. However, many conditions are managed in group
settings [12], reducing costs and providing peer support for patients. Studies evaluating group-based
physiotherapy for musculoskeletal conditions have revealed clinically irrelevant differences [12],
but there is little evidence examining this approach for shoulder pain.
The aim of this study was to review the equivalence of outcome between group and individual
physiotherapy in the treatment of SAI. An economic analysis was also conducted to compare health
service use and associated costs of the two groups.
The hypothesis is that physiotherapy treatment for shoulder impingement delivered as a series of
six rehabilitation classes will be as effective as individual physiotherapy treatment.
2. Methods
2.1. Study Design
This was a single-blind, open-label, randomised equivalence study comparing group and
individual physiotherapy. Ethical approval was obtained from the Office for Research Ethics
Committee, Northern Ireland (07/NIR01/79). The study was registered retrospectively at clinicatrails.gov
(Registration number NCT04058522).
2.2. Population
Patients referred by local general practitioners (GPs) and physiotherapists were considered for
inclusion. The patients included in the trial are therefore typical of primary care patients referred to
physiotherapy for management of their SAI symptoms. A physiotherapist (R.G.) screened patients for
inclusion and exclusion criteria (Table 1), obtained written informed consent approved by the ethical
committee and randomised them to treatment groups.
The Consolidated Standards of Reporting Trials (CONSORT) diagram is presented in Figure 1.
Data was not registered for patients assessed for eligibility but not recruited to the trial as this was not
considered at the time.
2.3. Intervention
Six rotator cuff rehabilitation classes: one class per week for six weeks (30 min length) aiming for
5–10 participants. Classes included advice on the condition, exercises for scapulo-humeral mobility
and stability, and specific rotator cuff rehabilitation exercises. One experienced band 6 physiotherapist
supervised each of the classes.
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Table 1. Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
• Adult subjects (≥18 years) with unilateral
shoulder pain of more than four weeks duration
• SPADI score of ≥30
• Shoulder pain was defined as pain in the
shoulder region, including the upper arm,
elicited by active or passive shoulder movement.
• The diagnosis of “subacromial pain” is defined
by range as: no limitation in passive range of
movement or restriction of passive range of
movement mainly in abduction rather than
external rotation [13].
• Inability to give informed consent
• Physiotherapy or injection treatment for current
shoulder pain in previous three months
• Blood coagulation disorders
• Bilateral shoulder pain
• Evidence of systemic infection
• Abnormal shoulder X-ray defined as significant
glenohumeral or subacromial joint space
narrowing suggesting Osteoarthritis of
glenohumeral joint or complete Rotator
Cuff rupture,
• Evidence of rotator cuff tear, tested by external
rotation lag sign, drop sign, internal rotation lag
sign and static muscle resistance in external
rotation, internal rotation and abduction
• History of significant trauma to the shoulder
• Inflammatory joint disease
• History of cerebrovascular accident
• Allergy or contraindication to
Triamcinolone/contraindication to injection.
• Evidence of referred pain from cervical
spine disease
• Pregnancy or breast feeding
• Patients whose first language is not English
2.4. Comparator
Routine individual physiotherapy: one session per week for six weeks (30 min). Treatment was
based on evidence-based guidelines for the treatment of SAI (CSP 2005) and consisted of mobilisation
techniques, supervised exercises and stretches. The physiotherapists taking the individual sessions
were of the same level of experience as in the group intervention and were able to select appropriate
treatments for each patient from this protocol based on their clinical judgement.
2.5. Steroid Injection
After randomisation all patients in both intervention and control groups received a single steroid
injection of Triamcinolone 40 mgs (1 mL) through a lateral approach to the subacromial space. This has
been shown to give short term pain relief [9], in order to facilitate patients to undertake a rehabilitation
programme. All injections were successfully administered, anatomically guided and performed by the
same GP (IR) experienced in musculoskeletal medicine, blinded to group allocation. An interval of
between one and three weeks was allowed between injection and commencement of physiotherapy.
2.6. Outcome Measures
Primary outcome: The primary outcome measure was the SPADI (shoulder pain and disability
index) at 26 weeks. The SPADI consists of 13 items that assess two domains: a five-item subscale
that measures pain (range 0–50) and an eight-item subscale that measures disability (range 0–80).
A higher score indicates greater impairment or disability [14]. The SPADI has previously been used
in primary care studies, including in rotator cuff disease [15]. A systematic review of the SPADI has
found reliability coefficients of ICC ≥ 0.89 in a variety of patient populations [16].
Secondary outcomes: Secondary outcomes were the active range of external rotation in neutral
position (measured by goniometer) and internal rotation (distance (centimetres)) between thumb tip
and C7 spinous process), global patient self-assessment measured by a 100mm visual analogue scale,
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and general health status with Short Form 36-item version 2 (SF36v2) [17], EuroQol 5-dimension 5-level
(EQ-5D-3L) [18] and Hospital Anxiety and Depression Scale (HADS) [19].
Outcomes were recorded at baseline, weeks 12, 26 and 52 by one researcher (R.G.) who was
blinded to all procedures.
2.7. Study Withdrawals
Patients were withdrawn from the study if they received additional steroid injections during
the study or if they were referred for ultrasound guided steroid injection at 12 or 26 weeks review
appointments. No further data was collected from patients withdrawn from the study.
2.8. Randomisation, Allocation Concealment and Blinding
The block randomisation technique was used to generate the randomisation schedule. The schedule
was generated using Microsoft Excel and the block size was 20. The randomisation allocations
were placed in opaque, sequentially numbered, sealed envelopes to ensure allocation concealment.
The envelopes were opened sequentially, after receiving patient consent. The outcome assessors were
blinded to the treatment allocations, and patients were instructed not to reveal their treatment group at
face to face assessments.
2.9. Sample Size Calculation
This was an equivalence trial. In order to detect the minimum clinically significant change of
±10 points [20] on the SPADI scale at 26 weeks, assuming a standard deviation of 23.5, with 80% power
and a significance level of 5% for a two-tailed analysis, 100 subjects per group was required, allowing
for 5% drop out rate.
2.10. Statistical Analysis
The primary outcome measure was the change in SPADI score between baseline and week 26.
The equivalence margin was set at (−10, +10) as this is reported as a clinically significant change in
Total SPADI score [20]. The 95% CI of mean difference (µ1−µ2) in Total SPADI score within the range
of −10 to +10 is therefore considered as the proof for the equivalence of both interventions. The null
hypothesis was that the treatments are not equivalent, i.e., (µ1−µ2) <= −10 or (µ1−µ2) >= 10. A two
one sided test (TOST) was used to test the hypothesis. The number of patients with 26 weeks SPADI
was low. A post-hoc analysis was carried out imputing the week 12 values for the patients who did not
have 26 week data. This was not included in the initial plan.
Secondary outcomes were summarised using n, Mean (SD), and Median (IQR). The difference
between the groups were compared using analysis of covariance, adjusting for the baseline values.
Stata 12.0 for Windows (Stata Corporation, College Station, TX, USA) and R 3.0.2 (R Foundation for
Statistical Computing. Vienna, Austria) was used for the data analysis.
2.11. Health Economic Analysis
Patient use of healthcare services related to their shoulder pain was collected at the 12, 26
and 52 week attendances by use of follow-up questionnaires. This included: intervention and
control physiotherapy attendance, contacts with general practitioner, accident and emergency visits,
additional physiotherapy, hospital investigations, outpatient attendances, analgesia and Non-Steroidal
Anti-inflammatory Drugs (NSAIDs) use, and other medications. The quantity of resource used was
multiplied by the appropriate unit costs. Steroid injections were not included as this was a cost common
to both arms of the trial.
Total health service cost was calculated by adding costs incurred at weeks 12, 26 and 52. Since
healthcare costs are typically skewed, non-parametric bootstrapping was also used to calculate 95%
bootstrap confidence intervals of differential mean costs.
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3. Results
3.1. Baseline Characteristics
A total of 136 patients in the age range 28.5 to 84.1 years was recruited to the study from September
2008 to February 2012. Recruitment was slow and was closed short of the expected recruitment of 200
due to time constraints on the researchers and funder. Baseline characteristics showed that patients
were predominantly female (61%), 83% were right arm dominant and 66% had right shoulder pain.
(Table 2) Symptoms had been present for a mean of 30 weeks in the intervention group and 33.5 weeks
in the control group. A small proportion reported shoulder pain post injury (26%), with 28% seeking
previous injections and 31% receiving previous physiotherapy. Effects of both these interventions were
not long lasting and with 45% in paid employment there was a considerable loss of working days due
to shoulder pain. There were no significant differences in baseline characteristics between the groups.
Table 2. Baseline Characteristics.
Variable Intervention Control
Number of patients (n) 68 68
Mean Age (SD) 54.5 (10.9) 58.1 (11.1)
Gender (n, %)
Female 44 (64.7) 39 (57.4)
Male 24 (35.3) 29 (42.6)
Ethnic origin (n, %)
Caucasian 68 (100) 66 (97)
Black 0 2 (2.9)
Paid employment (n, %)
No 34 (50) 41 (60.3)
Yes 34 (50) 27 (39.7)
Off work due to shoulder pain (n, %) 12 (35.3) 6 (22.2)
Lost working days (median, IQR) 14.5 (4–50) 42.5 (24–80)
Right hand dominance (n, %) 57 (83.8) 56 (82.4)
Painful shoulder (n, %)
Right 48 (70.6) 42 (61.8)
Left 20 (29.4) 26 (38.2)
Duration of episode (weeks, median, IQR) 30 (21–55) 33.5 (20–80)
Onset of shoulder pain (n, %)
Injury 20 (29.4) 16 (23.5)
Previous episodes of shoulder pain (n, %)
Yes 17 (25) 18 (26.5)
Number of episodes 3 (1–5) 2.5 (1–5)
Time since last episode 12 (7–48) 24 (7–60)
Previous shoulder injection
Yes (n, %) 16 (23.5) 22 (32.3)
No of injections (median, range) 1 (1–3) 1 (1–3)
Improved with injection (n, %) 13 (81.2) 13 (59.1)
Duration of improvement (weeks, mean, range) 8 (3–24) 19 (8–50)
Time since last injection (months, mean, range) 10 (7–15.5) 15.5 (7–36)
Previous physiotherapy for shoulder
Yes (n, %) 21 (30.9) 21 (30.9)
Improved with physiotherapy (n, %) 13 (61.9) 7 (33.3)
Time since physiotherapy (months, mean, range) 9 (5–48) 15 (9–24)
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3.2. Primary Outcome Measure
Table 3 summarises the SPADI Pain, Disability, and Total score at baseline, 12, 26 and 52 weeks.
The SPADI score in both the intervention and control arms indicated a reduction in all domains, with the
lowest scores at 52 weeks. The overall SPADI (from baseline to 26 weeks) demonstrated a difference (SE)
in mean change between the two groups of −0.43 (5.7) (p-value = 0.050001). The TOST (two one-sided
test for equivalence) 95% CI for this difference is given as (−10.0 to 9.14), which includes −10, supporting
the null hypothesis that the groups are not equivalent, i.e., the intervention (those receiving group
physiotherapy) have improved more than the control group (individual physiotherapy) (Table 4).
Table 3. Shoulder pain and disability index (SPADI) results–pain, disability and total score.
SPADI Score
Intervention Control
n Mean (SD) n Mean (SD)
SPADI–Pain
Baseline 68 74.6 (14.2) 68 76.4 (14.7)
Week 12 50 42.6 (32.4) 54 44.7 (29.9)
Week 26 35 43.4 (28.9) 37 44.4 (31.2)
Week 52 20 25.4 (28.2) 22 29.8 (29.7)
SPADI–Disability
Baseline 68 66.6 (16.4) 68 69.1 (17.2)
Week 12 50 30.0 (29.5) 54 36.0 (27.5)
Week 26 35 31.4 (26.3) 37 36.8 (29.8)
Week 52 20 16.6 (23.7) 22 21.9 (26.7)
SPADI–Total Score
Baseline 68 69.7 (14.9) 68 71.9 (15.7)
Week 12 50 34.9 (30.2) 54 39.4 (27.5)
Week 26 35 36.0 (26.5) 37 39.7 (29.7)
Week 52 20 20.0 (24.5) 22 25.0 (27.0)
Table 4. SPADI–Change from Baseline to 26 weeks.
SPADI
Mean (Standard Error)
Mean Difference (SE)
Intervention Control
Pain −27.6 (4.7) −30.3 (4.3) 2.7 (6.3)
Disability −33.6 (4.4) −31.2 (3.9) −2.4 (5.8)
Total Score −31.3 (4.3) −30.8 (3.8) −0.43 (5.7)
As the number completing SPADI at 26 weeks was low, secondary analysis was carried out.
Patients without SPADI data at week 26 were analysed by carrying forward scores obtained at week 12
to calculate the mean difference (SE) in the change between the groups. The null hypothesis that the
groups were not equivalent was rejected (mean difference (95% CI) =−0.14 (−7.5 to 7.3), p-value = 0.014).
Figure 2 shows the mean and 95% CI in SPADI Total score between the treatment arms at week 12, 26,
52. The mean and CI overlap significantly, implying that the SPADI remains similar in both groups.
3.3. Secondary Outcome Measures
Both groups showed improvement in secondary outcome measures but there was no significant
difference between groups, except for external rotation at 26 weeks favouring the control group
(p = 0.05).
For General Health Status, SF36v2, EQ-5D-3L and HAD, the only significant difference was at
12 weeks in the EQ-5D-3L favouring the intervention group (group physiotherapy) (p = 0.01).
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Figure 2. Mean (95% CI) for SPADI Total Score over time. (Intervention—Baseline n = 68, Week 12
n = 50, Week 26 n = 35, Week 52 n = 20; Control—Baseline n = 68, Week 12 n = 54, Week 26 n = 37,
Week 52 n = 22).
3.4. Physiotherapy
On average, both group and individual sessions lasted 30 min. There was no significant difference
in the number of sessions attended in both groups (mean sessions attended were 5.5 in the intervention
(group physiotherapy) group and 5 in the control (individual physiotherapy) group). Mean number of
participants per group was three. One patient in the intervention arm received routine physiotherapy
session instead of group session and three patients received group sessions instead of individual
physiotherapy due to an administration error in the physiotherapy department.
3.5. Health Economic Analysis
Not all pa ients rec ived the physiotherapy treatment that they were r ndomised to receive
(see Section 3.4), and not all pati nts attended ll six sessions. We therefore on y costed fo what they
actually received. Individual physiothe apy was costed at £42 er sess on (s e Table 5) and since it was
observed in the trial that an average of three patient attended the group physiotherapy (intervention)
sessions, we coste these at £14 per gro p session. Table 6 presents health service use costs at each
timepoint and Table 7 presents physiotherapy treatment costs and total costs (health service costs and
physiotherapy costs) related to shoulder pain. Medication costs were not included in the analysis as
this was poorly recorded. Health service use was slightly higher in the intervention arm, but differences
were small, and 95% confidence intervals were wide. Total health service use could only be calculated
for one-quarter of patients (intervention, n = 17; control, n = 17) who had complete cost data at all three
time points, making the results difficult to interpret. In this small sample of patients, health service
costs were higher for the intervention patients but there was overall cost saving in the intervention
arm due to the lower costs associated with delivering the physiotherapy treatment in a group setting.
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Table 5. Unit costs of health services (£ UK).
Resource Item Unit Cost Details Source
Practice GP visit 35
Per patient contact lasting 11.7
min. Excluding direct care staff
costs & qualifications
Unit costs of Health and
Social Care 2014 [21]
Accident & Emergency
visit 142
Weighted average of type 01
emergency medicine, admitted
and non-admitted.
NHS reference costs
2013–2014 [22]
Physiotherapy
attendance 42
Non-Admitted, face to face
follow-up attendance.
NHS reference costs
2013–2014 [22]
Rheumatology 92 Non-Admitted, face to facefollow-up attendance.
NHS reference costs
2013–2014 [22]
Trauma & Orthopaedic
outpatient attendance 105
Consultant led, non-admitted,
follow-up face to face attendance
NHS reference costs
2013–2014 [22]
Outpatient Clinic
attendance [unspecified] 109
weighted average of all outpatient
attendances
NHS reference costs
2013–2014 [22]
Analgesics various - British National Formulary68 (January 2015) [23]
Table 6. Cost (£) of health service use over the study period by group. Values are means (standard
deviations) unless otherwise stated.
Service Use
12 Weeks 26 Weeks 52 Weeks
Intervention Control Intervention Control Intervention Control
n Mean(sd) n
Mean
(sd) n
Mean
(sd) n
Mean
(sd) n
Mean
(sd) n
Mean
(sd)
Practice GP visit 50 4.2(18.22) 54
5.19
(19.71) 35
18.00
(73.21) 37
3.78
(11.02) 20
7.00
(31.30) 22 0 (0)
Accident & Emergency visit 50 0 (0) 54 0 (0) 35 8.11(48.00) 37 0 (0) 20 0 (0) 22 0 (0)
Physiotherapy attendance
(non-study treatment) 50
4.2
(29.70) 54
0.78
(5.72) 35 0 (0) 37 0 (0) 20
6.30
(28.17) 22 0 (0)
Outpatient attendances 50 4.2(20.78) 54 0 (0) 35
21.8
(98.21) 37 0 (0) 20
9.2
(41.14) 22 0 (0)
Mean health
services costs 50
12.60
(47.83) 54
5.96
(20.32) 35
47.91
(138.57) 37
3.78
(11.02) 20
31.70
(115.59) 22 0 (0)
Mean difference (bootstrap
95% CI) * 6.64 (−5.48, 21.25) 44.13 (5.38, 96.59) 31.70 (0, 85.75)
* Percentile confidence intervals based on 1000 bootstrap re-samples. Significance (p < 0.05) was judged where the
confidence intervals of differential means excluded zero.
Table 7. Service and treatment physiotherapy costs over the 52 weeks study period.
Costs
Intervention Control Mean Difference(Bootstrap 95% CI) *
n Mean (sd) n Mean (sd)
Total health service cost 17 79.65 (206.84) 17 2.06 (8.49) 77.59 (−1.62, 178.09)
Physiotherapy treatment cost 68 74.53 (33.64) 68 188.59 (96.01) −114.06 (−136.73, −89.38)
Overall cost 17 173.53 (206.81) 17 214.53 (83.45)254.06 (8.49) −41.00 (−129.20, 79.13)
* Percentile confidence intervals based on 1000 bootstrap resamples.
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4. Discussion
4.1. Summary
A total of 136 patients were recruited to the trial (68/68: Intervention/Control). Change in Total
SPADI score at 26 weeks from baseline was the primary outcome measure. The initial analysis
suggested that there was not equivalence between the groups, favouring the group physiotherapy arm.
However, there was a small sample size at week 26, resulting in a wider confidence interval, which
may have been the reason for this finding of non-equivalence. On secondary analysis (inputting data
from 12 weeks) the groups showed equivalence. The analysis of variance shows that the change in
SPADIs score was similar in both groups across the visits. Overall, there is little difference in outcome
at 26 weeks and no difference at 52 weeks. It can therefore be concluded that group physiotherapy
for SAI is cost saving and does not impact negatively on the health-related quality of life. The main
driver of the difference were the physiotherapy costs. Both groups received a similar number of
treatments, with the individual care costing £252 per patient treated compared to £84 for six group
sessions (based on an average of three patients per class), a cost saving of £168 per patient referred to
physiotherapy for shoulder impingement symptoms. The attendance rates were similar at the classes
compared with the individual sessions, highlighting that patients will commit to classes as well as to
individual treatments.
4.2. Strengths and Limitations
We acknowledge several limitations in the study. The recruitment fell short of the power calculation
of 200 (100 per group) and this may have contributed to the failure to show equivalence at the primary
endpoint. However, any difference in outcome at 26 weeks was toward the group physiotherapy
treatment arm and equivalence between treatment groups was shown at 12 weeks.
There were significant withdrawal rates as the study progressed, with few completing the study at
52 weeks. A frequent reason for patients dropping out of the study was to seek alternative management
outside the study protocol, for example, repeat corticosteroid injection or ultrasound guided injection.
The number of patients receiving further steroid injection was 10 (Intervention = 4, Control = 6) and
the number referred for ultrasound investigation with the potential for receiving a guided steroid
injection was 32 (Intervention = 19, Control = 13). The high attrition rate meant that only one quarter
of patients had complete cost data making the economic analysis results difficult to interpret.
Another consequence of slow recruitment was that we did not achieve our intended size of groups
(5–10) in the group physiotherapy, instead achieving three per class. Larger recruitment to classes
would have increased the cost saving.
4.3. Comparison with Existing Literature
There are several studies comparing individual and group physiotherapy in musculoskeletal
conditions [11]. Most of these focus on spinal pain. One study of frozen shoulder [24] showed superior
outcomes for a group exercise class over individual physiotherapy. This study suggested that peer
support and motivation, as well as fostering behavioural change via a self-management approach,
may have explained the difference in outcome. Another study compared physiotherapist supervised
group exercises with individual home exercise after a single information session with a physiotherapist
in patients with non-traumatic inoperable painful shoulder [25] This study found less functional
limitation at five weeks in those performing exercises in a group setting. This current study examines
subacromial shoulder pain and no other studies comparing group and individual physiotherapy in
this condition were found. Our study has found that for SAI patients group physiotherapy is at least
equivalent to individual physiotherapy, with potential for significant economic savings.
Various explanations for the lack of superiority of individual physiotherapy have been offered [11].
Group interventions spend time on exercise and education whereas individual approaches may include
more passive approaches. Exercise has been shown to have a positive effect on biopsychosocial factors
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associated with pain conditions [26] and this may be an effective aspect of both approaches. A group
approach may also increase social interaction between patients. This peer support may be an advantage
of the group approaches by addressing more of the psychosocial issues associated with painful
conditions. A group approach may address the multidimensional biopsychosocial needs of these
patients more effectively than an individual approach which may be more focused on physical factors.
4.4. Implications for Research and/or Practice
The cost saving of group-based approaches with similar outcomes has implications for commissioning
and planning of shoulder pain treatment. With long NHS waiting times for musculoskeletal interventions
including for physiotherapy, a group-based approach may increase the capacity of services without
compromising clinical effectiveness.
Further research should address which aspects of physiotherapy treatment contribute to its
effectiveness in treating shoulder pain. It is not known what should be included in a group-based
programme and how much emphasis should there be on education and approaches addressing the
biopsychosocial model. For example, can a stratification of care approach identify which patients may
benefit more from an individual or group approach to treatment?
Group based physiotherapy treatment for subacromial shoulder pain is therefore a cost saving
approach with similar clinical outcome to individual physiotherapy.
4.5. How This Fits in to Clinical Practice
Shoulder pain is a common problem in primary care with physiotherapy and subacromial
corticosteroid injection commonly used to treat subacromial impingement (SAI). Group based
approaches to physiotherapy have been explored in other musculoskeletal conditions but not
in SAI when preceded by corticosteroid injection. With increasing engagement of first contact
physiotherapists in the primary care multidisciplinary team, exploration of the most cost-effective
approach to physiotherapy for SAI is important. In this study we show that group-based physiotherapy
for SAI is cost saving compared with individual physiotherapy with similar clinical outcomes.
5. Conclusions
There is little difference in outcome between group and individual physiotherapy following
corticosteroid injection for SAI at 26 weeks and no difference at 52 weeks. Group physiotherapy was
cheaper to deliver per patient. Group physiotherapy for SAI produces similar clinical outcomes to
individual physiotherapy with potential cost savings. Due to low recruitment to and high drop out
from our study, firm conclusions are difficult and further research is required to give a definitive
answer to this research question.
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